Innoviva Net Interest Income Over Time
| INVA Stock | USD 19.05 0.09 0.47% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Innoviva Performance and Innoviva Correlation. Innoviva |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Earnings Share 0.8 | Revenue Per Share 5.6 | Quarterly Revenue Growth 0.331 | Return On Assets 0.0937 |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Interest Income Analysis
Compare Innoviva and related stocks such as Effector Therapeutics, Protalix Biotherapeutics, and PDS Biotechnology Corp Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (9.5 M) | (7.1 M) | (7.6 M) | (9.2 M) | (7.1 M) | (1.4 M) | (1.9 M) | (2 M) |
| PDSB | (991.4 K) | (991.4 K) | (991.4 K) | (991.4 K) | (991.4 K) | (991.4 K) | (991.4 K) | (1.5 M) | (553.4 K) | 319.9 K | 55 K | 4.3 K | (381.3 K) | (1.1 M) | (1.2 M) |
| ELEV | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (500 K) | (300 K) | (315 K) |
| DAWN | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (30 K) | 4 K | 4.7 M | 5.5 M | 5.7 M |
| TERN | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 1.2 M | 55 K | 170 K | 2.1 M | 12.9 M | 13.5 M |
| APLS | (96.9 K) | (96.9 K) | (96.9 K) | (96.9 K) | (96.9 K) | (96.9 K) | (96.9 K) | (96.9 K) | 447.8 K | (175.8 K) | (25.8 M) | (12.8 M) | (23.7 M) | (8.6 M) | (9.1 M) |
| XFOR | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (1.9 M) | (230 K) | (950 K) | (2.4 M) | (3.6 M) | (3.8 M) | (1.7 M) | (1.8 M) |
| INZY | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 284 K | 1.1 M | 370 K | 211 K | 1.9 M | 4.1 M | 4.3 M |
| HOOK | (606 K) | (606 K) | (606 K) | (606 K) | (606 K) | (606 K) | (606 K) | (606 K) | (778 K) | 710 K | (386 K) | (871 K) | 946 K | 4.6 M | 4.8 M |
| ABOS | 45 K | 45 K | 45 K | 45 K | 45 K | 45 K | 45 K | 45 K | 45 K | 45 K | 1000 | 84 K | 2.4 M | 8.2 M | 8.6 M |
| FOLD | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (13.1 M) | (11.9 M) | (8.6 M) | (19.2 M) | (32 M) | (34.1 M) | (41 M) | (39 M) |
| INCY | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | (34.3 M) | 10.6 M | (1.5 M) | (1.9 M) | (2.2 M) | (1.9 M) | (2.7 M) | 106.2 M | 111.5 M |
| DNLI | 781 K | 781 K | 781 K | 781 K | 781 K | 781 K | 781 K | 2 M | 10.1 M | 15.2 M | 9.2 M | 4.6 M | 14.8 M | 45 M | 47.3 M |
| ARGX | 61 K | 61 K | 61 K | 61 K | 61 K | 61 K | 61 K | 165 K | 1.4 M | 7.8 M | (1.4 M) | (944 K) | 23.8 M | 92.1 M | 96.7 M |
| HRMY | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (6.1 M) | (28.2 M) | (24 M) | (15.7 M) | (11.9 M) | (12.5 M) |
Innoviva and related stocks such as Effector Therapeutics, Protalix Biotherapeutics, and PDS Biotechnology Corp Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
Check out Innoviva Performance and Innoviva Correlation. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Innoviva technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.